Skip to main content

Table 1 Clinical characteristics of study participants undergoing controlled ovarian hyperstimulation (COH) assessed before and after oocyte retrieval

From: DNA methylome profiling of granulosa cells reveals altered methylation in genes regulating vital ovarian functions in polycystic ovary syndrome

Parameters assessed

Control (n = 20) median (IQR)

PCOS (n = 20) median (IQR)

P value

Age in years

30.0 (27.0–31.0)

31.5 (28.0–33.0)

0.124

BMI (kg m−2)

23.03 (20.97–25.06)

24.65 (22.24–27.76)

0.173

#Basal FSH (μU/mL)

7.64 (5.52–9.39)

5.71 (4.39–6.61)

0.037*

#Basal LH (μU/mL)

6.19 (3.0–7.66)

9.13 (5.58–12.24)

0.02*

#LH:FSH

0.75 (0.55–1.04)

1.74 (1.15–2.04)

0.0001***

#Prolactin (ng/mL)

14.2 (12.0–18.27)

14.48 (11.72–24.3)

0.43

#TSH (mIU/mL)

1.8 (1.14–2.75)

2.36 (1.55–4.08)

0.0577

#AMH (ng/mL)

3.4 (1.94–7.86)

7.99 (5.21–9.74)

0.0094**

Regular cycle

20 (100%)

3 (15%)

 

Oligomenorrhea

0 (0%)

15 (80%)

<0.0001***

Secondary amenorrhea

0 (0%)

2 (5%)

 

rFSH (IU)

1600 (1528–2313)

1706 (1350–2025)

0.788

E2 (ng/mL) before hCG administration

1.49 (1.247–2.24)

2.03 (1.22–2.47)

0.367

E2 (ng/mL) on hCG administration day

1.71 (1.436–2.32)

2.56 (1.82–3.72)

0.038*

P4 (ng/mL) before hCG administration

0.3 (0.2–0.55)

0.25 (0.17–0.525)

0.522

P4 (ng/mL) on hCG administration day

2.65 (2.07–4.05)

4.6 (1.95–6.32)

0.200

Total follicles (n)

15.0 (12.0–20.5)

18.5 (15.0–29.25)

0.099

Total oocytes (n)

13.5 (10.0–17.25)

16.5 (14.5–26.75)

0.059

MII oocytes (n)

10.5 (8.0–13.5)

15.0 (9.0–19.75)

0.057

MII oocytes (%)

82.84 (70.24–90.71)

86.85 (74.2–95.31)

0.366

Total fertilized oocytes (n)

6.0 (4.5–9.25)

6.5 (3.75–14.5)

0.464

Rate of MII oocyte fertilization (ROF)

65.63 (51.92–88.13)

52.27 (34.8–67.)

0.039*

$E2 (ng/mL) Serum

0.2 (0.15–0.6)

0.43 (0.15–0.76)

0.418

$E2 (ng/mL) FF

374 (178.6–541.7)

280.3 (125–819)

0.586

$P4 (ng/mL) Serum

1 (3–9)

3.9 (0.3–7.)

0.903

$P4 (ng/mL) FF

8170 (4760–15,880)

6000 (3280–10,140)

0.325

$TT (ng/dL) Serum

126 (89–178.5)

172.6 (140–311.3)

0.020*

$TT (ng/dL) FF

300 (140.2–372.6)

405.8 (222.6–639.3)

0.030*

$SHBG (nmol/L) Serum

130 (103.0–150.0)

95 (79–134.5)

0.041*

$SHBG (nmol/L) FF

158 (127.8–205.5)

127.7 (103.3–148.8)

0.024*

$Free T (pmol/L) Serum

3.53 (2.07–4.85)

6.03 (3.93–9.73)

0.066

$Free T (pmol/L) FF

4.24 (1.55–7.87)

7.5 (5.28–11.74)

0.050*

$Bio-T (nmol/L) Serum

0.82 (0.48–1.14)

1.09 (0.8–1.9)

0.033*

$Bio-T (nmol/L) FF

0.99 (0.58–1.84)

1.75 (1.24–2.74)

0.050*

$FAI serum

3.03 (2.38–6.48)

6.03 (3.93–9.73)

0.035*

$FAI FF

3.7 (2.32–7.17)

6.93 (5.48–13.42)

0.050*

  1. Data are represented as median (inter-quartile range) for anthropometric and hormonal characteristics compared been controls and women with PCOS using Mann-Whitney U tests. Parameters marked with asterisk (#) denote those measured between days 3–5 of the menstrual cycle (early follicular phase) before initiating the controlled ovarian hyperstimulation (COH) procedure. Parameters marked by “$” were measured in sera and follicular fluids obtained on the day of ovum pick up (d-OPU). Menstrual characteristics were assessed using the chi-square analysis. P values < 0.05 are considered significant for all statistical tests. *P <  0.05, **P <  0.01, ***P </= 0.0001 have been indicated. BMI body-mass index, E2 estradiol, P4 progesterone, TT total testosteronem, SHBG sex hormone binding globulin, Bio-T bioavailable testosterone, Free-T free testosterone, FAI free androgen index.
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us